AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11872998
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (zidovudine, lamivudine, and indinavir)
Trial: 11872998
Drug: Both concentration-controlled
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both concentration-controlled and conventional therapy
Trial: 9607949
Drug: Nonliposomal (oil/water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonliposomal (oil/water cream) delivery system
Trial: 30734476
Drug: Ultrasound-guided cervical
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided cervical nerve root block (CRB) with mixed drug liquid
Trial: 29045212
Drug: 5-mg tofacitinib
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg tofacitinib
Trial: 29045212
Drug: 10-mg tofacitinib
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg tofacitinib
Trial: 29045212
Drug: placebo (switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (switched to 5-mg tofacitinib at 3 months)
Trial: 29045212
Drug: placebo (switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (switched to 10-mg tofacitinib at 3 months)
Trial: 16952814
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of morphine in 10 mL of saline
Trial: 10195529
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of saline
Trial: 9322512
Drug: Fructose-glucose (FruGlu)
RxNorm normalized name: fructose / glucose / phosphoric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose-glucose (FruGlu) solution
Trial: 9322512
Drug: Fructose-glucose-acarbose (FruGluA)
RxNorm normalized name: fructose / glucose / phosphoric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose-glucose-acarbose (FruGluA) solution
Trial: 9322512
Drug: Lactulose absorption
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose absorption from glucose or sucrose solutions
Trial: 9322512
Drug: Fructose-mannitol (FruMann)
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose-mannitol (FruMann) solution
Trial: 9322512
Drug: Sucrose, FruGlu,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose, FruGlu, and glucose solutions
Trial: 8373602
Drug: Midazolam (MZ)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (MZ) 0.02 mg/kg i.v., repeated every 2 to 3 minutes; maintenance MZ 0.005 mg/kg i.v. as necessary
Trial: 8373602
Drug: Propofol bolus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol bolus (PB) 0.75 to 1.0 mg/kg i.v.; maintenance 0.25 mg/kg i.v. as necessary
Trial: 8373602
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (PI) 2 to 4 mg/kg/hr or 33 to 66 micrograms/kg/min to maintain SL3
Trial: 3539031
Drug: Nebulised beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised beclomethasone dipropionate suspension
Trial: 30171484
Drug: Mannitol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (12 g)
Trial: 25234606
Drug: Active transcranial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcranial direct current stimulation (tDCS) administered in 15 30-minute treatments over three weeks
Trial: 25234606
Drug: Sham condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham condition administered in 15 30-minute treatments over three weeks
Trial: 18269775
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m2 twice daily for 14 days followed by 7 days of rest
Trial: 18269775
Drug: Capecitabine 1000
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 twice daily
Trial: 10595949
Drug: (99m)Tc‐sestamibi injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc‐sestamibi injection (20 to 30 mCi) before primary angioplasty
Trial: 1878612
Drug: Videotaped behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotaped behavioral treatment program
Trial: 6682026
Drug: Naloxone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusion at a rate of 20 micrograms kg‐1 hr‐1
Trial: 3887976
Drug: Oral tiaramide
RxNorm normalized name: stearamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tiaramide 200 mg four times daily
Trial: 3887976
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol 4 mg four times daily
Trial: 3887976
Drug: Oral tiaramide
RxNorm normalized name: stearamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tiaramide
Trial: 25355194
Drug: Paracetamol/acetaminophen 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/acetaminophen 500 mg thrice daily
Trial: 25355194
Drug: Placebo (empty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (empty capsules)
Trial: 20158920
Drug: Aerobic-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic-based exercise training (6 months, thrice-weekly)
Trial: 2500169
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg twice daily for 16 weeks
Trial: 2500169
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg twice daily for 16 weeks
Trial: 815189
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg, three times a day for 2 days)
Trial: 10206132
Drug: Early dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early dexamethasone treatment (from day 7)
Trial: 10206132
Drug: Late dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Late dexamethasone treatment (from day 14)
Trial: 7774174
Drug: Fluoride therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride therapy only (control group)
Trial: 2078794
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (radiation in combination with 5-FU)
Trial: 22331521
Drug: Hibiscus sabdariffa
RxNorm normalized name: HIBISCUS SABDARIFFA CALYX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscus sabdariffa L. aqueous extract (HSE)
Trial: 20089827
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg/d for 1 week
Trial: 16900082
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 supplementation (1-18 microg/daily)
Trial: 15338103
Drug: Methylphenidate (30
RxNorm normalized name: methylphenidate (30/70 release) 10 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (30 mg single dose)
Trial: 10850384
Drug: Consensus Interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consensus Interferon (CIFN), 9 microg, subcutaneous injection, three times weekly for 24 weeks
Trial: 10850384
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b (IFN alfa‐2b), 3 MU, subcutaneous injection, three times weekly for 24 weeks
Trial: 10850384
Drug: Serotype or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype or genotype 2 or 3 (independently of treatment)
Trial: 8565197
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate ophthalmic solution (0.1%)
Trial: 7020900
Drug: alpha-methyldopa (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-methyldopa (750 mg/d orally)
Trial: 7020900
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alpha-methyldopa and chlorothiazide
Trial: 19533165
Drug: Citalopram (CITAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (CITAL 2 x 10 mg)
Trial: 19533165
Drug: Placebo (PLA:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA: lactose 2 x 10 mg)
Trial: 17207172
Drug: EGF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF (10 microg/g) in 0.1% silver sulfadiazine cream
Trial: 17207172
Drug: 0.1% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% silver sulfadiazine cream alone
Trial: 12075760
Drug: AZM 10
RxNorm normalized name: Azmiro
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZM 10 mg/kg/day
Trial: 12075760
Drug: AZM 20
RxNorm normalized name: Azmiro
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZM 20 mg/kg/day
Trial: 9793623
Drug: Klimonorm (Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Klimonorm (Test preparation)
Trial: 9793623
Drug: Klimonorm (Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Klimonorm (Test preparation) and Reference preparation
Trial: 2941493
Drug: Recombinant alpha-2
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha-2 interferon (rIFN-alpha 2) at a dosage of 2 X 10(6) units, administered three times per week for one year
Trial: 29843276
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (Control Group)
Trial: 26638130
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g four times a day for 5 days
Trial: 23886272
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ10) treatment in FM patients
Trial: 21481958
Drug: Levosimendan (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.3 mg/kg/min, administered weekly for 6h over 6 months)
Trial: 21481958
Drug: Dobutamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (10 mg/kg/min, administered weekly for 6h over 6 months)
Trial: 21481958
Drug: Dobutamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (10 mg/kg/min) + Levosimendan (0.2 mg/kg/min, administered weekly for 6h over 6 months)
Trial: 2404837
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to the other platinum compound (carboplatin if initially treated with cisplatin, and vice versa)
Trial: 2404837
Drug: Rechallenged with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rechallenged with the same drug (cisplatin or carboplatin)
Trial: 7304657
Drug: Single-dose cefaclor
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose cefaclor (2 g orally)
Trial: 7304657
Drug: Multidose cefaclor
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidose cefaclor (250 mg orally three times a day for 10 days)
Trial: 7304657
Drug: Single-dose cefaclor
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose cefaclor (2 g orally) with ACB test (less inclusive criteria)
Trial: 7304657
Drug: Multidose cefaclor
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidose cefaclor (250 mg orally three times a day for 10 days) with ACB test (less inclusive criteria)
Trial: 28780479
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) + docetaxel (D)
Trial: 17223870
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolaevulinate (MAL) cream (160 mg g(‐1)) applied for 3 hours
Trial: 17223870
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied for 3 hours
Trial: 7610529
Drug: Doxycyclin 2
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycyclin 2 x 100 mg p. o. for at least 14 days or Cefuroxim 2 x 500 mg if contraindicated
Trial: 7610529
Drug: Ceftriaxon 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxon 1 x 2‐‐2 x 2 g i. v. or Cefotaxim 3 x 2 g i. v. for at least 14 days
Trial: 2782043
Drug: L-dopa 100
RxNorm normalized name: L-DOPA 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa 100 mg plus benserazide 25 mg
Trial: 959118
Drug: Killed influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed influenza vaccine given by injection
Trial: 959118
Drug: Selective vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective vaccination for high-risk groups (e.g., elderly, key workers)
Trial: 26065919
Drug: P2-VP8 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2-VP8 vaccine (10, 30, or 60 μg)
Trial: 26065919
Drug: P2-VP8 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2-VP8 vaccine (60 μg)
Trial: 26065919
Drug: P2-VP8 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2-VP8 vaccine (any dose)
Trial: 22924571
Drug: GH (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (dose based on IGF-I titration algorithm; n = 114)
Trial: 21422084
Drug: IVIg (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (0.75 g/kg)
Trial: 19527189
Drug: Local oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local oestrogen therapy
Trial: 19527189
Drug: Drugs enhancing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs enhancing nitric oxide or vasoactive intestinal polypeptide
Trial: 19527189
Drug: Phosphodiesterase inhibitors
RxNorm normalized name: Phosphodiesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase inhibitors
Trial: 19527189
Drug: Local administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local administration of dihydroepiandrosterone
Trial: 14722892
Drug: Lopinavir/ritonavir 800/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir 800/200 mg once daily
Trial: 11139311
Drug: Oral paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral paclitaxel (120 mg/m²) with GF120918 (1000 mg)
Trial: 11139311
Drug: Oral paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral paclitaxel (120 mg/m²) with CsA (previous study)
Trial: 11139311
Drug: Intravenous paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous paclitaxel (175 mg/m²)
Trial: 9596394
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 100 BTA U into the tibialis posterior muscle, followed by ankle-foot taping (group B)
Trial: 9596394
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 190 to 320 BTA U into several calf muscles (group A)
Trial: 7889428
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate Aqueous Nasal Spray (FPANS) 200 micrograms once daily
Trial: 7889428
Drug: Terfenadine tablets
RxNorm normalized name: terfenadine Oral Tablet
DrugBank: Terfenadine (DB00342)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terfenadine tablets (60 mg) twice daily
Trial: 3498406
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg . kg‐1 propofol
Trial: 3498406
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg . kg‐1 methohexitone
Trial: 3498406
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg . kg‐1 with fentanyl 1.5 micrograms . kg‐1
Trial: 3498406
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 micrograms . kg‐1 with vecuronium 0.1 mg . kg‐1
Trial: 3498406
Drug: Methohexitone 2
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone 2 mg . kg‐1
Trial: 19549706
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off)
Trial: 19549706
Drug: Interferon-alpha (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (9 million units s.c. injection three times/week)
Trial: 16512083
Drug: Explicit, systematic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Explicit, systematic reading intervention in Spanish for treatment group (daily for 50 min)
Trial: 12649125
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus recombinant surfactant protein C surfactant (Venticute) given four times over 24 hours
Trial: 30883859
Drug: Treatment switched
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment switched at an HIV-RNA threshold of 1000 copies/ml
Trial: 26772449
Drug: Daily zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily zinc supplement
Trial: 23978948
Drug: Fentanyl 3
RxNorm normalized name: FENTANYL 37.5MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 3 μg/ml
Trial: 17472485
Drug: 300 mg/1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/1.2 g NT-GA combination
Trial: 17472485
Drug: 600 mg/2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/2.4 g NT-GA combination
Trial: 12575373
Drug: Fluticasone inhalation
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone inhalation combined with Jinacon (JNC)
Trial: 12575373
Drug: Fluticasone inhalation
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone inhalation alone
Trial: 9649143
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg day(-1)
Trial: 2656777
Drug: Tonazocine mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonazocine mesylate 4 mg
Trial: 2656777
Drug: Tonazocine mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonazocine mesylate 8 mg
Trial: 1080959
Drug: Pharmacologic doses
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic doses of steroids administered early in the shock state (within the first hour) for periods of less than forty-eight hours
Trial: 28359172
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral airway only)
Trial: 25933111
Drug: Cisplatin/Gemcitabine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/Gemcitabine (up to six cycles; cisplatin 75 mg/m2 [d1]; gemcitabine 1000 mg/m2 [d1,8])
Trial: 16009445
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg/day for 12 weeks
Trial: 16009445
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg/day followed by Fenofibrate 200 mg/day for an additional 12 weeks
Trial: 14959471
Drug: Standard drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drugs plus bicycle exercise (group 1)
Trial: 14959471
Drug: Standard drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drugs only (group 2)
Trial: 8442964
Drug: IV ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ondansetron (two 8 mg doses 8 hours apart)
Trial: 20850097
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg and Clopidogrel 75 mg for 6 months
Trial: 10705425
Drug: Subcutaneous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous lidocaine around the sheath site
Trial: 9373656
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days treatment with Quinimax® (10 mg/kg twice daily)